Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00084266
Status:
COMPLETED
Last Update Posted:
2012-02-01
First Post:
2004-06-09
Brief Title:
Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus MRSA
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Linezolid In The Treatment Of Subjects With Nosocomial Pneumonia Proven To Be Due To Methicillin-Resistant Staphylococcus Aureus
Status:
COMPLETED
Status Verified Date:
2012-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ZEPHYR
Brief Summary:
To determine if linezolid is superior to vancomycin in the treatment of nosocomial acquired in the hospital pneumonia due to Methicillin Resistant Staphylococcus Aureus MRSA in adult subjects Subjects entered in to the study will have proven healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia which will be treated with either linezolid or vancomycin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None